Center-Authored Papers

Browse: Authors | Keywords | All Center-Authored Publications
Filter by Division: Basic | Clinical | Human Biology | PHS | VIDD (2010-present) | VIDI (2008-2009)
Filter by Year: 2008 | 2009 | 2010 | 2011 | 2012 | 2013

Filters: Author is Higano, Celestia S  [Clear All Filters]
A
Akfirat, C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD et al..  2013.  Tumor Cell Survival Mechanisms in Lethal Metastatic Prostate Cancer Differ Between Bone and Soft Tissue Metastases.. The Journal of pathology. Abstract
C
Cheever, MA, Higano CS.  2011.  PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(11):3520-6. Abstract
H
Higano, CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford DE.  2008.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.. Cancer. 112(10):2181-7. Abstract
Higano, CS, Crawford DE.  2011.  New and emerging agents for the treatment of castration-resistant prostate cancer.. Urologic oncology. 29(6 Suppl):S1-8. Abstract
Higano, CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.
Higano, CS.  2012.  Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(30):3720-5. Abstract
Higano, CS.  2012.  New treatment options for patients with metastatic castration-resistant prostate cancer.. Cancer treatment reviews. 38(5):340-5. Abstract
Hirata, Y, Akakura K, Higano CS, Bruchovsky N, Aihara K.  2012.  Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.. Journal of molecular cell biology. 4(3):127-32. Abstract
Holcomb, IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS et al..  2009.  Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.. Cancer research. 69(19):7793-802. Abstract
Hussain, M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Hussain, M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
K
Kantoff, P, Higano CS.  2012.  Integration of immunotherapy into the management of advanced prostate cancer.. Urologic oncology. 30(5 Suppl):S41-7. Abstract
L
Larson, SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B et al..  2013.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.. The Prostate. Abstract
Lord, JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB.  2010.  Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.. Digestive diseases and sciences. 55(5):1396-405. Abstract
M
Menon, MP, Higano CS.  2013.  Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.. Current oncology reports. 15(2):69-75. Abstract
Mohler, JL, Armstrong AJ, Bahnson RR, Boston B, Busby EJ, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS et al..  2012.  Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(9):1081-1087. Abstract
Montgomery, BR, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.  2008.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.. Cancer research. 68(11):4447-54. Abstract
Morrissey, C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang Y-C, Corey E, Lange PH et al..  2008.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.. Clinical & experimental metastasis. 25(4):377-88. Abstract
Q
Qian, DZ, Huang C-Y, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS et al..  2009.  Prostate cancer-associated gene expression alterations determined from needle biopsies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(9):3135-42. Abstract
Qian, DZ, Rademacher BLS, Pittsenbarger J, Huang C-Y, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.  2010.  CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.. The Prostate. 70(4):433-42. Abstract
R
Ryan, CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
S
Sonpavde, G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.  2012.  The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.. European urology. 61(4):639-647. Abstract
T
Tangen, CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
Y
Yu, EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Yu, EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.  2012.  Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(15):1864-70. Abstract